Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021).
de la Haba-Rodriguez J, Lloret FF, Salgado MAV, Arce MO, Gutiérrez AC, Jiménez JG, Zambrano CB, Alonso RMR, López RL, Salas NR. de la Haba-Rodriguez J, et al. Among authors: jimenez jg. Clin Transl Oncol. 2022 Apr;24(4):693-702. doi: 10.1007/s12094-022-02817-8. Epub 2022 Apr 1. Clin Transl Oncol. 2022. PMID: 35362851 Free PMC article.
Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients.
Sevillano Fernández E, Madurga de Lacalle R, Rodriguez Moreno JF, Barquín García A, Yagüe Fernández M, Navarro Alcaraz P, Barba Llacer M, Quiralte Pulido M, García-Donás Jiménez J. Sevillano Fernández E, et al. Among authors: garcia donas jimenez j. J Clin Med. 2022 Aug 1;11(15):4483. doi: 10.3390/jcm11154483. J Clin Med. 2022. PMID: 35956100 Free PMC article.
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.
Bellmunt Molins J, García-Donas Jiménez J, Valderrama BP, Virizuela Echaburu JA, Hernando-Polo S, Climent Durán MÁ, Villa-Guzmán JC, Arranz Arija JÁ, Ostiategui ML, Milagro NL, González-Del-Alba A, González BM, Díaz EG, Gauna DC, Santasusana MD, Herranz UA, Del Muro Solans XG, Pérez-Gracia JL, Vázquez JP, Morales-Barrera R, Pous AF. Bellmunt Molins J, et al. Among authors: garcia donas jimenez j. Clin Genitourin Cancer. 2020 Dec;18(6):452-460. doi: 10.1016/j.clgc.2020.05.004. Epub 2020 May 11. Clin Genitourin Cancer. 2020. PMID: 32565133 Clinical Trial.
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Vergote I, et al. Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7. Lancet Oncol. 2019. PMID: 31076365 Free article. Clinical Trial.